References
- Organization WH. Clinical management of severe acute respiratory
infection (SARI) when COVID-19 disease is suspected.Interim guidance V
1.2. 2020.
- Dong X, Cao YY, Lu XX, Zhang JJ, Du H, Yan YQ, et al. Eleven faces of
coronavirus disease 2019. Allergy 2020.
- Xu Y, Li X, Zhu B, Liang H, Fang C, Gong Y, et al. Characteristics of
pediatric SARS-CoV-2 infection and potential evidence for persistent
fecal viral shedding. Nat Med 2020;26(4):502-505.
- Recalcati S. Cutaneous manifestations in COVID-19: a first
perspective. J Eur Acad Dermatol Venereol 2020.
- Monteagudo LA, Boothby A, Gertner E. Continuous Intravenous Anakinra
Infusion to Calm the Cytokine Storm in Macrophage Activation Syndrome.ACR Open Rheumatol 2020.
- Zhang C, Wu Z, Li JW, Zhao H, Wang GQ. The cytokine release syndrome
(CRS) of severe COVID-19 and Interleukin-6 receptor (IL-6R) antagonist
Tocilizumab may be the key to reduce the mortality. Int J
Antimicrob Agents 2020:105954.
- Zhou M, Zhang X, Qu J. Coronavirus disease 2019 (COVID-19): a clinical
update. Front Med 2020.
- Sanders JM, Monogue ML, Jodlowski TZ, Cutrell JB. Pharmacologic
Treatments for Coronavirus Disease 2019 (COVID-19): A Review.JAMA 2020.
- Du YX, Chen XP. Favipiravir: Pharmacokinetics and Concerns About
Clinical Trials for 2019-nCoV Infection. Clin Pharmacol Ther2020.
- Health TMo. Turkish Ministry ofHealth COVID-19 Guideline 14.04.2020.
2020.
- Direzione Generale Cura della Persona SeW. Indirizzi terapeutici della
Regione E-R per il trattamento della infezione da SARS-CoV2
(COVID-19). 2020.
- Garvey LH, Ebo DG, Mertes PM, Dewachter P, Garcez T, Kopac P, et al.
An EAACI position paper on the investigation of perioperative
immediate hypersensitivity reactions. Allergy2019;74(10):1872-1884.
- Romano A, Atanaskovic-Markovic M, Barbaud A, Bircher AJ, Brockow K,
Caubet JC, et al. Towards a more precise diagnosis of hypersensitivity
to beta-lactams - an EAACI position paper. Allergy 2019.
- Aberer W, Bircher A, Romano A, Blanca M, Campi P, Fernandez J, et al.
Drug provocation testing in the diagnosis of drug hypersensitivity
reactions: general considerations. Allergy 2003;58(9):854-863.
- Brockow K, Ardern-Jones MR, Mockenhaupt M, Aberer W, Barbaud A, Caubet
JC, et al. EAACI position paper on how to classify cutaneous
manifestations of drug hypersensitivity. Allergy2019;74(1):14-27.
- Gomes ER, Brockow K, Kuyucu S, Saretta F, Mori F, Blanca-Lopez N, et
al. Drug hypersensitivity in children: report from the pediatric task
force of the EAACI Drug Allergy Interest Group. Allergy2016;71(2):149-161.
- Brockow K, Garvey LH, Aberer W, Atanaskovic-Markovic M, Barbaud A,
Bilo MB, et al. Skin test concentrations for systemically administered
drugs - an ENDA/EAACI Drug Allergy Interest Group position paper.Allergy 2013;68(6):702-712.
- Mayorga C, Celik G, Rouzaire P, Whitaker P, Bonadonna P,
Rodrigues-Cernadas J, et al. In vitro tests for drug hypersensitivity
reactions: an ENDA/EAACI Drug Allergy Interest Group position paper.Allergy 2016;71(8):1103-1134.
- Cernadas JR, Brockow K, Romano A, Aberer W, Torres MJ, Bircher A, et
al. General considerations on rapid desensitization for drug
hypersensitivity - a consensus statement. Allergy2010;65(11):1357-1366.
- Scherer K, Brockow K, Aberer W, Gooi JH, Demoly P, Romano A, et al.
Desensitization in delayed drug hypersensitivity reactions – an
EAACI position paper of the Drug Allergy Interest Group.Allergy 2013;68(7):844-852.
- Guan WJ, Ni ZY, Hu Y, Liang WH, Ou CQ, He JX, et al. Clinical
Characteristics of Coronavirus Disease 2019 in China. N Engl J
Med 2020.
- Galván Casas C, Català A, Carretero Hernández G, Rodríguez-Jiménez P,
Fernández Nieto D, Rodríguez-Villa Lario A, et al. Classification of
the cutaneous manifestations of COVID-19: a rapid prospective
nationwide consensus study in Spain with 375 cases. Br J Dermatol.
2020 Apr 29.
- Henry D, Ackerman M, Sancelme E, Finon A, Esteve E. Urticarial
eruption in COVID-19 infection. J Eur Acad Dermatol Venereol2020.
- Hunt M, Koziatek C. A Case of COVID-19 Pneumonia in a Young Male with
Full Body Rash as a Presenting Symptom. Clin Pract Cases Emerg
Med 2020.
- Marzano AV, Genovese G, Fabbrocini G, Pigatto P, Monfrecola G,
Piraccini BM, et al. Varicella-like exanthem as a specific
COVID-19-associated skin manifestation: multicenter case series of 22
patients. J Am Acad Dermatol 2020.
- Genovese G, Colonna C, Marzano AV. Varicella-like exanthem associated
with COVID-19 in an 8-year-old girl: A diagnostic clue? Pediatr
Dermatol 2020.
- Jimenez-Cauhe J, Ortega-Quijano D, Prieto-Barrios M, Moreno-Arrones
OM, Fernandez-Nieto D. Reply to ”COVID-19 can present with a rash and
be mistaken for Dengue”: Petechial rash in a patient with COVID-19
infection. J Am Acad Dermatol 2020.
- Hedou M, Carsuzaa F, Chary E, Hainaut E, Cazenave-Roblot F, Masson
Regnault M. Comment on ”Cutaneous manifestations in COVID-19: a first
perspective ” by Recalcati S. J Eur Acad Dermatol Venereol2020.
- Gianotti R, Veraldi S, Recalcati S, Cusini M, Ghislanzoni M, Boggio F,
et al. Cutaneous Clinico-Pathological Findings in three
COVID-19-Positive Patients Observed in the Metropolitan Area of Milan,
Italy. Acta Derm Venereol 2020.
- Joob B, Wiwanitkit V. COVID-19 can present with a rash and be mistaken
for dengue. J Am Acad Dermatol 2020;82(5):e177.
- Manalo IF, Smith MK, Cheeley J, Jacobs R. A Dermatologic Manifestation
of COVID-19: Transient Livedo Reticularis. J Am Acad Dermatol2020.
- Kolivras A, Dehavay F, D. D, Feoli F, Meiers I, Milone L, et al.
Coronavirus (COVID-19) infection-induced chilblains: a case report
with histopathological findings. JAAD Case Reports 2020.
- Mazzotta F, Troccoli T, Bonifazi E. A new vasculitis at the time of
COVID-19. European Journal Of Pediatric Dermatology - pd online2020.
- Fernandez-Ni”eto D, Jimenez-Cauhe J, Suarez-Valle A,
Moreno-Arrones OM, Saceda-Corralo D, Arana-Raja A, et al.
Characterization of acute acro-ischemic lesions in non-hospitalized
patients: a case series of 132 patients during the COVID-19 outbreak.
J Am Acad Dermatol. 2020 Apr 24. pii: S0190-9622(20)30709-X.
- Zhang Y, Cao W, Xiao M, Li YJ, Yang Y, Zhao J, et al. [Clinical and
coagulation characteristics of 7 patients with critical COVID-2019
pneumonia and acro-ischemia]. Zhonghua Xue Ye Xue Za Zhi2020;41(0):E006.
- Magro C, Mulvey JJ, Berlin D, Nuovo G, Salvatore S, Harp J, et al.
Complement associated microvascular injury and thrombosis in the
pathogenesis of severe COVID-19 infection: A report of five cases.Transl Res 2020.
- Zhai P, Ding Y, Wu X, Long J, Zhong Y, Li Y. The epidemiology,
diagnosis and treatment of COVID-19. Int J Antimicrob Agents2020:105955.
- Li G, De Clercq E. Therapeutic options for the 2019 novel coronavirus
(2019-nCoV). Nat Rev Drug Discov 2020;19(3):149-150.
- Jean SS, Lee PI, Hsueh PR. Treatment options for COVID-19: The reality
and challenges. J Microbiol Immunol Infect 2020.
- Costanzo M, De Giglio MAR, Roviello GN. SARS-CoV-2: Recent Reports on
Antiviral Therapies Based on Lopinavir/Ritonavir,
Darunavir/Umifenovir, Hydroxychloroquine, Remdesivir, Favipiravir and
Other Drugs for the Treatment of the New Coronavirus. Curr Med
Chem 2020.
- Rosa
SGV, Santos WC.
Clinical trials on drug repositioning for COVID-19 treatment. Rev
Panam Salud Publica. 2020;44:e40.
- Jefferson T, Jones M, Doshi P, Spencer EA, Onakpoya I, Heneghan CJ.
Oseltamivir for influenza in adults and children: systematic review of
clinical study reports and summary of regulatory comments. BMJ2014;348:g2545.
- Simin M, Brok J, Stimac D, Gluud C, Gluud LL. Cochrane systematic
review: pegylated interferon plus ribavirin vs. interferon plus
ribavirin for chronic hepatitis C. Aliment Pharmacol Ther2007;25(10):1153-1162.
- Cao B, Wang Y, Wen D, Liu W, Wang J, Fan G, et al. A Trial of
Lopinavir-Ritonavir in Adults Hospitalized with Severe COVID-19.N Engl J Med 2020.
- Madruga JV, Berger D, McMurchie M, Suter F, Banhegyi D, Ruxrungtham K,
et al. Efficacy and safety of darunavir-ritonavir compared with that
of lopinavir-ritonavir at 48 weeks in treatment-experienced,
HIV-infected patients in TITAN: a randomised controlled phase III
trial. Lancet 2007;370(9581):49-58.
- Zuo W, Wen LP, Li J, Mei D, Fu Q, Zhang B. Oseltamivir induced
Stevens-Johnson syndrome/toxic epidermal necrolysis-case report.Medicine (Baltimore) 2019;98(19):e15553.
- Gonzalez-Ramos J, Lamas C, Bellon T, Ruiz-Bravo E, Ramirez E, Lerma V,
et al. Oseltamivir-induced toxic epidermal necrolysis in a patient
with Cushing’s disease. Indian J Dermatol Venereol Leprol 2019.
- Grein J, Ohmagari N, Shin D, Diaz G, Asperges E, Castagna A, et al.
Compassionate use of Remdesivir for Patients with Severe COVID-19.N Engl J Med 2020.
- Brillanti S, Mazzella G, Roda E. Ribavirin for chronic hepatitis C:
and the mystery goes on. Dig Liver Dis 2011;43(6):425-430.
- Lorcy S, Gaudy-Marqueste C, Botta D, Portal I, Quiles N, Oulies V, et
al. [Cutaneous adverse events of telaprevir/peginterferon/ribavirin
therapy for chronic hepatitis C: A multicenter prospective cohort
study]. Ann Dermatol Venereol 2016;143(5):336-346.
- Patrk I, Morovic M, Markulin A, Patrk J. Cutaneous reactions in
patients with chronic hepatitis C treated with peginterferon and
ribavirin. Dermatology 2014;228(1):42-46.
- Brok J, Gluud LL, Gluud C. Meta-analysis: ribavirin plus interferon
vs. interferon monotherapy for chronic hepatitic C - an updated
Cochrane review. Aliment Pharmacol Ther 2010;32(7):840-850.
- Barreira P, Cadinha S, Malheiro D, da Silva JP. Delayed
hypersensitivity to ribavirin confirmed by provocation test. J
Investig Allergol Clin Immunol 2014;24(6):441-442.
- Shindo M, Terai I. Adverse Skin Reactions due to Ribavirin in
Hepatitis C Combination Therapy with Pegylated Interferon-alpha2a.Case Rep Dermatol 2013;5(3):379-381.
- Ladd AM, Martel-Laferriere V, Dieterich D. Successful desensitization
to ribavirin in a patient with chronic hepatitis C. J Clin
Gastroenterol 2012;46(8):716-717.
- Toker O, Tal Y, Daher S, Shalit M. Ribavirin Desensitization in
Chronic Hepatitis C. Isr Med Assoc J 2015;17(9):583-584.
- Corbett AH, Lim ML, Kashuba AD. Kaletra (lopinavir/ritonavir).Ann Pharmacother 2002;36(7-8):1193-1203.
- Ghosn J, Duvivier C, Tubiana R, Katlama C, Caumes E. Acute generalized
exanthematous pustulosis induced by HIV postexposure prophylaxis with
lopinavir-ritonavir. Clin Infect Dis 2005;41(9):1360-1361.
- Echeverria P, Negredo E, Carosi G, Galvez J, Gomez JL, Ocampo A, et
al. Similar antiviral efficacy and tolerability between efavirenz and
lopinavir/ritonavir, administered with abacavir/lamivudine (Kivexa),
in antiretroviral-naive patients: a 48-week, multicentre, randomized
study (Lake Study). Antiviral Res 2010;85(2):403-408.
- Sun L, Deng X, Chen X, Huang J, Huang S, Li Y, et al. Incidence of
adverse drug reactions in COVID-10 patients in China: An active
monitoring study by hospital pharmacovigilance system. Clin Pharmacol
Ther 2020 Apr 23.
- Molina JM, Cohen C, Katlama C, Grinsztejn B, Timerman A, Pedro Rde J,
et al. Safety and efficacy of darunavir (TMC114) with low-dose
ritonavir in treatment-experienced patients: 24-week results of POWER
3. J Acquir Immune Defic Syndr 2007;46(1):24-31.
- Buijs BS, van den Berk GE, Boateng CP, Hoepelman AI, van Maarseveen
EM, Arends JE. Cross-reactivity between darunavir and
trimethoprim-sulfamethoxazole in HIV-infected patients. AIDS2015;29(7):785-791.
- Marcos Bravo MC, Ocampo Hermida A, Martinez Vilela J, Perez Rodriguez
MT, Gavilan Montenegro MJ, Arenas Villarroel LJ, et al.
Hypersensitivity reaction to darunavir and desensitization protocol.J Investig Allergol Clin Immunol 2009;19(3):250-251.
- Lorber M, Haddad S. Hypersensitivity and desensitization to darunavir
in a case of HIV infection with triple-class drug resistance: case
description and review of the literature. J Int Assoc Provid
AIDS Care 2013;12(6):378-379.
- Hirschfeld G, Weber L, Renkl A, Scharffetter-Kochanek K, Weiss JM.
Anaphylaxis after Oseltamivir (Tamiflu) therapy in a patient with
sensitization to star anise and celery-carrot-mugwort-spice syndrome.Allergy 2008;63(2):243-244.
- Tran DH, Sugamata R, Hirose T, Suzuki S, Noguchi Y, Sugawara A, et al.
Azithromycin, a 15-membered macrolide antibiotic, inhibits influenza
A(H1N1)pdm09 virus infection by interfering with virus internalization
process. J Antibiot (Tokyo) 2019;72(10):759-768.
- Gautret P, Lagier JC, Parola P, Hoang VT, Meddeb L, Mailhe M, et al.
Hydroxychloroquine and azithromycin as a treatment of COVID-19:
results of an open-label non-randomized clinical trial. Int J
Antimicrob Agents 2020:105949.
- Araujo L, Demoly P. Macrolides allergy. Curr Pharm Des2008;14(27):2840-2862.
- Mori F, Pecorari L, Pantano S, Rossi ME, Pucci N, De Martino M, et al.
Azithromycin anaphylaxis in children. Int J Immunopathol
Pharmacol 2014;27(1):121-126.
- Barni S, Butti D, Mori F, Pucci N, Rossi ME, Cianferoni A, et al.
Azithromycin is more allergenic than clarithromycin in children with
suspected hypersensitivity reaction to macrolides. J Investig
Allergol Clin Immunol 2015;25(2):128-132.
- Schissel DJ, Singer D, David-Bajar K. Azithromycin eruption in
infectious mononucleosis: a proposed mechanism of interaction.Cutis 2000;65(3):163-166.
- Milkovic-Kraus S, Macan J, Kanceljak-Macan B. Occupational allergic
contact dermatitis from azithromycin in pharmaceutical workers: a case
series. Contact Dermatitis 2007;56(2):99-102.
- Mendes-Bastos P, Bras S, Amaro C, Cardoso J. Non-occupational allergic
contact dermatitis caused by azithromycin in an eye solution. J
Dtsch Dermatol Ges 2014;12(8):729-730.
- An I, Demir V, Akdeniz S. Fixed drug eruption probably induced by
azithromycin. Australas J Dermatol 2017;58(4):e253-e254.
- Campanon-Toro MV, Sierra O, Moreno E, Sobrino-Garcia M, Gracia-Bara
MT, Davila I. Acute generalized exanthematous pustulosis (AGEP)
induced by azithromycin. Contact Dermatitis 2017;76(6):363-364.
- Sriratanaviriyakul N, Nguyen LP, Henderson MC, Albertson TE. Drug
reaction with eosinophilia and systemic symptoms syndrome (DRESS)
syndrome associated with azithromycin presenting like septic shock: a
case report. J Med Case Rep 2014;8:332.
- Aihara Y, Ito S, Kobayashi Y, Aihara M. Stevens-Johnson syndrome
associated with azithromycin followed by transient reactivation of
herpes simplex virus infection. Allergy 2004;59(1):118.
- Xu L, Zhu Y, Yu J, Deng M, Zhu X. Nursing care of a boy seriously
infected with Steven-Johnson syndrome after treatment with
azithromycin: A case report and literature review. Medicine
(Baltimore) 2018;97(1):e9112.
- Odemis E, Kalyoncu M, Okten A, Yildiz K. Azithromycin-induced
leukocytoclastic vasculitis. J Rheumatol 2003;30(10):2292.
- Pursnani A, Yee H, Slater W, Sarswat N. Hypersensitivity myocarditis
associated with azithromycin exposure. Ann Intern Med2009;150(3):225-226.
- Empedrad R, Darter AL, Earl HS, Gruchalla RS. Nonirritating
intradermal skin test concentrations for commonly prescribed
antibiotics. J Allergy Clin Immunol 2003;112(3):629-630.
- Won HK, Yang MS, Song WJ, Kim SH, Park HW, Chang YS, et al.
Determination of nonirritating concentrations of antibiotics for
intradermal skin tests in Korean adults. J Allergy Clin Immunol
Pract 2017;5(1):192-194 e192.
- Seitz CS, Brocker EB, Trautmann A. Suspicion of macrolide allergy
after treatment of infectious diseases including Helicobacter pylori:
results of allergological testing. Allergol Immunopathol (Madr)2011;39(4):193-199.
- Unal D, Demir S, Gelincik A, Olgac M, Coskun R, Colakoglu B, et al.
Diagnostic value of oral challenge testing in the diagnosis of
macrolide hypersensitivity. J Allergy Clin Immunol Pract 2018;6:521-7.
- Staso P, Leonov A. Drug desensitization in 17-year-old male with Mast
Cell Activation Syndrome, pneumonia, and antibiotic
hypersensitivities. AME Case Rep 2017;1:7.
- Sinha N, Balayla G. Hydroxychloroquine and COVID-19. Postgrad
Med J 2020.
- Soria A, Barbaud A, Assier H, Avenel-Audran M, Tetart F, Raison-Peyron
N, et al. Cutaneous Adverse Drug Reactions with Antimalarials and
Allergological Skin Tests. Dermatology 2015;231(4):353-359.
- Matsuda T, Ly NTM, Kambe N, Nguyen CTH, Ueda-Hayakawa I, Son Y, et al.
Early cutaneous eruptions after oral hydroxychloroquine in a lupus
erythematosus patient: A case report and review of the published work.J Dermatol 2018;45(3):344-348.
- Sidoroff A, Dunant A, Viboud C, Halevy S, Bavinck JN, Naldi L, et al.
Risk factors for acute generalized exanthematous pustulosis
(AGEP)-results of a multinational case-control study (EuroSCAR).Br J Dermatol 2007;157(5):989-996.
- Volpe A, Marchetta A, Caramaschi P, Biasi D, Bambara LM, Arcaro G.
Hydroxychloroquine-induced DRESS syndrome. Clin Rheumatol2008;27(4):537-539.
- Schmutz JL, Barbaud A, Trechot P. [Hydroxychloroquine and DRESS].Ann Dermatol Venereol 2008;135(12):903.
- Girijala RL, Siddiqi I, Kwak Y, Wright D, Patel DB, Goldberg LH.
Pustular DRESS Syndrome Secondary to Hydroxychloroquine With EBV
Reactivation. J Drugs Dermatol 2019;18(2):207-209.
- Perez-Ezquerra PR, de Barrio Fernandez M, de Castro Martinez FJ, Ruiz
Hornillos FJ, Prieto Garcia A. Delayed hypersensitivity to
hydroxychloroquine manifested by two different types of cutaneous
eruptions in the same patient. Allergol Immunopathol (Madr)2006;34(4):174-175.
- Phillips-Howard PA, Warwick Buckler J. Idiosyncratic reaction
resembling toxic epidermal necrolysis caused by chloroquine and
maloprim. Br Med J (Clin Res Ed) 1988;296(6636):1605.
- Kanny G, Renaudin JM, Lecompte T,
Moneret-Vautrin DA. Chloroquine hypersensitivity syndrome. Eur J
Intern Med 2002;13(1):75-76.
- Murphy M, Carmichael AJ. Fatal toxic epidermal necrolysis associated
with hydroxychloroquine. Clin Exp Dermatol 2001;26(5):457-458.
- Cameron MC, Word AP, Dominguez A.
Hydroxychloroquine-induced fatal toxic epidermal necrolysis
complicated by angioinvasive rhizopus. Dermatol Online J2014;20(11).
- Lisi P, Assalve D, Hansel K.
Phototoxic and photoallergic dermatitis caused by hydroxychloroquine.Contact Dermatitis 2004;50(4):255-256.
- Meier H, Elsner P, Wuthrich B.
[Occupationally-induced contact dermatitis and bronchial asthma in a
unusual delayed reaction to hydroxychloroquine]. Hautarzt1999;50(9):665-669.
- Charfi O, Kastalli S, Sahnoun R, Lakhoua G. Hydroxychloroquine-induced
acute generalized exanthematous pustulosis with positive
patch-testing. Indian J Pharmacol 2015;47(6):693-694.
- Mates M, Zevin S, Breuer GS, Navon P, Nesher G. Desensitization to
hydroxychloroquine–experience of 4 patients. J Rheumatol2006;33(4):814-816.
- Caramaschi P, Barbazza R, Tinazzi
I, Biasi D. Desensitization to hydroxychloroquine: 4 cases. J
Rheumatol 2011;38(10):2267; author reply 2267.
- Tal Y, Maoz Segal R, Langevitz P,
Kivity S, Darnizki Z, Agmon-Levin N. Hydroxychloroquine
desensitization, an effective method to overcome hypersensitivity-a
multicenter experience. Lupus 2018;27(5):703-707.
- Barailler H, Milpied B, Chauvel A,
Claraz P, Taieb A, Seneschal J, et al. Delayed hypersensitivity skin
reaction to hydroxychloroquine: Successful short desensitization.J Allergy Clin Immunol Pract 2019;7(1):307-308.
- Rowane M, Schend J, Patel J,
Hostoffer R, Jr. Rapid desensitization of hydroxychloroquine.Ann Allergy Asthma Immunol 2020;124(1):97-98.
- Donado CD, Diez EM. Successful desensitization for hydroxychloroquine
anaphylaxis. J Rheumatol 2010;37(9):1975-1976. X
- Perez-Sanchez N, Esponda-Juarez K,
Cimarra Alvarez M, Aleo Lujan E, Toledano Martinez E, Fernandez-Rivas
MM. Short desensitization in an adolescent with hydroxychloroquine
anaphylaxis. Pediatr Allergy Immunol 2014;25(8):819-821.
- Rothan HA, Stone S, Natekar J, Kumari P, Arora
K, Kumar M. The FDA-
approved gold drug Auranofin inhibits novel coronavirus (SARS-COV-2)
replication and attenuates inflammation in human cells.
https://www.biorxiv.org/content/10.1101/2020.04.14.041228v1.
- Morgenstern B, Michaelis M, Baer PC, Doerr HW, Cinatl J, Jr. Ribavirin
and interferon-beta synergistically inhibit SARS-associated
coronavirus replication in animal and human cell lines. Biochem
Biophys Res Commun 2005;326(4):905-908.
- Sheahan TP, Sims AC, Leist SR, Schafer A, Won J, Brown AJ, et al.
Comparative therapeutic efficacy of remdesivir and combination
lopinavir, ritonavir, and interferon beta against MERS-CoV. Nat
Commun 2020;11(1):222.
- Vazquez-Lopez F, Manjon-Haces JA,
Perez-Alvarez R, Perez-Oliva N. Eczema-like lesions and disruption of
therapy in patients treated with interferon-alfa and ribavirin for
chronic hepatitis C: the value of an interdisciplinary assessment.Br J Dermatol 2004;150(5):1046-1047; author reply 1047.
- Kerl K, Negro F, Lubbe J.
Cutaneous side-effects of treatment of chronic hepatitis C by
interferon alfa and ribavirin. Br J Dermatol 2003;149(3):656.
- Calabresi PA, Kieseier BC, Arnold
DL, Balcer LJ, Boyko A, Pelletier J, et al. Pegylated interferon
beta-1a for relapsing-remitting multiple sclerosis (ADVANCE): a
randomised, phase 3, double-blind study. Lancet Neurol2014;13(7):657-665.
- Milkiewicz P, Yim C, Pache I,
Heathcote J. Diffuse skin reaction in patient with hepatitis B,
treated with two different formulations of pegylated interferon.Can J Gastroenterol 2005;19(11):677-678.
- Cottoni F, Bolognini S, Deplano A,
Garrucciu G, Manzoni NE, Careddu GF, et al. Skin reaction in antiviral
therapy for chronic hepatitis C: a role for polyethylene glycol
interferon? Acta Derm Venereol 2004;84(2):120-123.
- Poreaux C, Bronowicki JP, Debouverie M, Schmutz JL, Waton J, Barbaud
A. Clinical allergy. Managing generalized interferon-induced eruptions
and the effectiveness of desensitization. Clin Exp Allergy2014;44(5):756-764.
- Sidhu-Malik NK, Kaplan AL. Multiple fixed drug eruption with
interferon/ribavirin combination therapy for hepatitis C virus
infection. J Drugs Dermatol 2003;2(5):570-573.
- Conroy M, Sewell L, Miller OF, Ferringer T. Interferon-beta injection
site reaction: review of the histology and report of a lupus-like
pattern. J Am Acad Dermatol 2008;59(2 Suppl 1):S48-49.
- Brown DL, Login IS, Borish L, Powers PL. An urticarial IgE-mediated
reaction to interferon beta-1b. Neurology2001;56(10):1416-1417.
- Kalpaklioglu FA, Baccioglu Kavut
A, Erdemoglu AK. Desensitization in interferon-beta1a allergy: a case
report. Int Arch Allergy Immunol 2009;149(2):178-180.
- Cortellini G, Amadori A, Comandini T, Corvetta A. Interferon beta 1a
anaphylaxis, a case report. Standardization of non-irritating
concentration for allergy skin tests. Eur Ann Allergy Clin
Immunol 2013;45(5):181-182.
- Sakatani A, Doi Y, Matsuda T, Sasai Y, Nishida N, Sakamoto M, et al.
Protracted anaphylaxis developed after peginterferon alpha-2a
administration for chronic hepatitis C. World J Gastroenterol2015;21(9):2826-2829.
- Meller S, Erhardt A, Auci A, Neumann NJ, Homey B. Drug-induced
exanthema caused by pegylated interferon-alpha 2b. Hautarzt2003;54(10):992-993.
- Taghavi SA, Eshraghian A.
Successful interferon desensitization in a patient with chronic
hepatitis C infection. World J Gastroenterol2009;15(33):4196-4198.
- Caly L, Druce JD, Catton MG, Jans
DA, Wagstaff KM. The FDA-approved drug ivermectin inhibits the
replication of SARS-CoV-2 in vitro. Antiviral Res2020;178:104787.
- Ngwasiri CA, Abanda MH, Aminde LN. Ivermectin-induced fixed drug
eruption in an elderly Cameroonian: a case report. J Med Case
Rep 2018;12(1):254.
- Kerneuzet I, Blind E, Darrieux L, Moreau S, Safa G. Ivermectin-induced
drug reaction with eosinophilia and systemic symptoms (DRESS)
syndrome. JAAD Case Rep 2018;4(6):524-527.
- Aroke D, Tchouakam DN, Awungia AT, Mapoh SY, Ngassa SN, Kadia BM.
Ivermectin induced Steven-Johnsons syndrome: case report. BMC
Res Notes 2017;10(1):179.
- Seegobin K, Bueno E, Maharaj S, Ashby T, Brown M, Jones L. Toxic
epidermal necrolysis after ivermectin. Am J Emerg Med2018;36(5):887-889.
- Kelleni MT. Nitazoxanide/Azithromycin Combination for COVID-19: A
Suggested New Protocol for COVID-19 Early Management. Pharmacol
Res. 2020 Apr 30;104874.
- Regnier Galvao V, Castells MC. Hypersensitivity to biological agents-
Updated diagnosis, management and treatment. J Allegy Clin Immunol
Pract. 2015;3:174-185.
- Nakamura M, Tokura Y. Tocilizumab-induced erythroderma. Eur J
Dermatol 2009;19(3):273-274.
- Yoshiki R, Nakamura M, Tokura Y. Drug eruption induced by IL-6
receptor inhibitor tocilizumab. J Eur Acad Dermatol Venereol2010;24(4):495-496.
- Soyer O, Demir S, Bilginer Y, Batu ED, Sonmez HE, Arici ZS, et al.
Severe hypersensitivity reactions to biological drugs in children with
rheumatic diseases. Pediatr Allergy Immunol 2019;30(8):833-840.
- Koc R, Sonmez HE, Cakan M, Karadag SG, Tanatar A, Cakmak F, et al.
Drug reactions in children with rheumatic diseases receiving
parenteral therapies: 9 years’ experience of a tertiary pediatric
rheumatology center. Rheumatol Int 2020;40(5):771-776.
- Rocchi V, Puxeddu I, Cataldo G, Del Corso I, Tavoni A, Bazzichi L, et
al. Hypersensitivity reactions to tocilizumab: role of skin tests in
diagnosis. Rheumatology (Oxford) 2014;53(8):1527-1529.
- Tetu P, Hamelin A, Moguelet P, Barbaud A, Soria A. Management of
hypersensitivity reactions to Tocilizumab. Clin Exp Allergy2018;48(6):749-752.
- Cortellini G, Mascella F, Simoncelli M, Lippolis D, Focherini MC,
Cortellini F, et al. Effective Desensitization to Tocilizumab in
Delayed Hypersensitivity Reaction. Pharmacology2018;102(1-2):114-116.
- Ben Said B, Gerfaud-Valentin M, Seve P. Fatal DRESS syndrome under
tocilizumab treatment for seronegative polyarthritis. J Allergy
Clin Immunol Pract 2018;6(3):1048-1049.
- Zuelgaray E, Domont F, Peiffer-Smadja N, Saadoun D, Cacoub P.
Tocilizumab-Induced Drug Reaction With Eosinophilia and Systemic
Symptoms Syndrome in Adult-Onset Still Disease. Ann Intern Med2017;167(2):141-142.
- Villiger PM, Adler S, Kuchen S, Wermelinger F, Dan D, Fiege V, et al.
Tocilizumab for induction and maintenance of remission in giant cell
arteritis: a phase 2, randomised, double-blind, placebo-controlled
trial. Lancet 2016;387(10031):1921-1927.
- Izquierdo JH, Bonilla-Abadia F, Ochoa CD, Agualimpia A, Tobon GJ,
Canas CA. Acute Generalized Exanthematous Pustulosis due to
Tocilizumab in a Rheumatoid Arthritis Patient. Case Rep
Rheumatol 2012;2012:517424.
- Yasuoka R, Iwata N, Abe N, Kohagura T, Nakaseko H, Shimizu M, et al.
Risk factors for hypersensitivity reactions to tocilizumab
introduction in systemic juvenile idiopathic arthritis. Mod
Rheumatol 2019;29(2):324-327.
- den Broeder AA, de Jong E, Franssen MJ, Jeurissen ME, Flendrie M, van
den Hoogen FH. Observational study on efficacy, safety, and drug
survival of anakinra in rheumatoid arthritis patients in clinical
practice. Ann Rheum Dis 2006;65(6):760-762.
- Kaiser C, Knight A, Nordström D, Petterson T, Fransson J, Robertsson
EF. Injection-site reactions upon Kineret (anakinra) administration:
experiences and explanations. Rheumatol Int (2012) 32:295–299. DOI
10.1007/s00296-011-2096-3.
- Soyyigit S, Kendirlinan R, Aydin O, Celik GE. Successful
desensitization with anakinra in a case with immediate
hypersensitivity reaction. Ann Allergy Asthma Immunol2014;113(3):325-326.
- Desai D, Goldbach-Mansky R, Milner JD, Rabin RL, Hull K, Pucino F, et
al. Anaphylactic reaction to anakinra in a rheumatoid arthritis
patient intolerant to multiple nonbiologic and biologic
disease-modifying antirheumatic drugs. Ann Pharmacother2009;43(5):967-972.
- Yılmaz I, Turk M, Nazik
Bahcecioglu S. Successful rapid subcutaneous desensitization to
anakinra in a case with a severe immediate-type hypersensitivity
reaction. Eur Ann Allergy Clin Immunol 2018;50(2):94-96.
- Emmi G, Silvestri E, Cantarini L, Lopalco G, Cecchi L, Chiarini F, et
al. Rapid desensitization to anakinra-related delayed reaction: Need
for a standardized protocol. J Dermatol 2017;44(8):981-982.
- Bendele A, Colloton M, Vrkljan M,
Morris J, Sabados K. Cutaneous mast cell degranulation in rats
receiving injections of recombinant human interleukin-1 receptor
antagonist (rhIL-1ra) and/or its vehicle: possible clinical
implications. J Lab Clin Med 1995;125(4):493-500.
- Lu CC, Chen MY, Chang YL. Potential therapeutic agents against
COVID-19: What we know so far? J Chin Med Assoc. 2020 Apr
1;10.1097/JCMA.0000000000000318.
- Wells AF. Parrino J, Mangan EK, Paccaly A, Lin Y,. Xu C, et al.
Immunogenicity of sarilumab monotherapy in patients with rheumatoid
arthritis who were inadequate responders or intolerant to
disease-modifying antirheumatic drugs. Rheumatol Ther (2019)
6:339–352.
- Grom AA, Horne A, De Benedetti F. Macrophage activation syndrome in
the era of biologic therapy. Nat Rev Rheumatol2016;12(5):259-268.
- Favalli EG, Biggioggero M, Maioli G, Caporali R.
Baricitinib for COVID-19:
a suitable treatment? Lancet Infect Dis. 2020 Apr
3:S1473-3099(20)30262-0. doi: 10.1016/S1473-3099(20)30262-0.
- Stebbing
J,
Phelan
A,
Griffin
I,
Tucker
C,
Oechsle
O,
Smith
D, et al. COVID-19: combining antiviral and anti-inflammatory
treatments.
Lancet
Infect Dis. 2020 Apr; 20(4): 400–402.
- Fournier JB, Cummings F, Cannella J. Drug-associated skin lesions in a
patient with myelofibrosis receiving ruxolitinib. Dermatol Online J.
2014 Oct 15;20(10). pii: 13030/qt2jg3q02x
- Koumaki D, Koumaki V, Lagoudaki E, Bertsias G. Palmoplantar
pustulosis-like eruption induced by baricitinib for treatment of
rheumatoid athritis. Eur J Case rep Intern Med 2019; 19: 7(1):001383.
- Doohan BJ, Cranwell WC, Varigos GA, De Cruz R. An urticarial drug
eruption caused by tofacitinib for alopecia universalis. Dermatologic
Therapy. 2019;32:e12933.
- Shibata T, Muto J, Hirano Y, Hiroyuki T, Yanagishita T, Ohshima Y, et
al. Palmoplantar pustulosis-like eruption following tofacitinib
therapy for juvenile idiopathic arthritis. Ohshima,JAAD Case Reports
2019;5:518-21.
- de Wilde AH, Zevenhoven-Dobbe JC, van der Meer Y, Thiel V, Narayanan
K, Makino S, et al. Cyclosporin A inhibits the replication of diverse
coronaviruses. Journal of General Virology (2011), 92, 2542–2548. DOI
10.1099/vir.0.034983-0.
- Volcheck GW, Van Dellen RG. Anaphylaxis to intravenous cyclosporine
and tolerance to oral cyclosporine: case report and review. Ann
Allergy Asthma Immunol 1998;80(2):159-163.
- Kang SY, Sohn KH, Lee JO, Kim SH, Cho SH, Chang YS. Intravenous
tacrolimus and cyclosporine induced anaphylaxis: what is next?Asia Pac Allergy 2015;5(3):181-186.
- Ebo DG, Piel GC, Conraads V, Stevens WJ. IgE-mediated anaphylaxis
after first intravenous infusion of cyclosporine. Ann Allergy
Asthma Immunol 2001;87(3):243-245.
- Deftereos SG, Siasos G, Giannopoulos G, Vrachatis DA, Angelidis C,
Giotaki SG, et al. The Greek study in the Effects of Colchicine in
Covid-19 complications prevention (GRECCO-19 study): rationale and
study design. Hellenic J Cardiol J 2020 Apr 3;S1109-9666(20)30061-0.
doi: 10.1016/j.hjc.2020.03.002.
- Mochida K, Teramae H, Hamada T. Fixed drug eruption due to colchicine.
Dermatology 1996;192:61.
- Levinger U, Monselise A. Reporting a desensitization protocol for
colchicine treatment. Clin Exp Rheumatol 2001;19(5 Suppl 24):S79.
- Barbaud A, Trechot P, Reichert-Penetrat S, Commun N, Schmutz JL.
Relevance of skin tests with drugs in investigating cutaneous adverse
drug reactions. Contact Dermatitis. 2001 Nov;45(5):265-8.
- Diurno F, Numis FG, Porta G, Cirillo F, Maddaluno S, Ragozzino A, et
al. Eculizumab treatment in patients with COVID-19: preliminary
results from real life ASL Napoli 2 Nord experience. Eur Rev Med
Pharmacol Sci 2020;24(7):4040-4047.
- Misawa S, Kuwabara S, Sato Y,
Yamaguchi N, Nagashima K, Katayama K, et al. Safety and efficacy of
eculizumab in Guillain-Barre syndrome: a multicentre, double-blind,
randomised phase 2 trial. Lancet Neurol 2018;17(6):519-529.
- Rondeau E, Cataland SR, Al-Dakkak
I, Miller B, Webb NJA, Landau D. Eculizumab Safety: Five-Year
Experience From the Global Atypical Hemolytic Uremic Syndrome
Registry. Kidney Int Rep 2019;4(11):1568-1576.
- Lo R, Alexander S, Moss J, Siddiqi
A, Liu A. Eculizumab hypersensitivity and desensitization in a toddler
with atypical hemolytic uremic syndrome. J Allergy Clin Immunol
Pract 2019;7(7):2409-2410.
- Russell CD, Millar JE, Baillie JK. Clinical evidence does not support
corticosteroid treatment for 2019-nCoV lung injury. Lancet2020;395(10223):473-475.
- Zhou W, Liu Y, Tian D, Wang C, Wang S, Cheng J, et al. Potential
benefits of precise corticosteroids therapy for severe 2019-nCoV
pneumonia. Signal Transduct Target Ther 2020;5(1):18.
- Li T, Lu H, Zhang W. Clinical observation and management of COVID-19
patients. Emerg Microbes Infect 2020;9(1):687-690.
- Ventura MT, Calogiuri GF, Muratore L, Di Leo E, Buquicchio R,
Ferrannini A, et al. Cross-reactivity in cell-mediated and
IgE-mediated hypersensitivity to glucocorticoids. Curr Pharm
Des 2006;12(26):3383-3391.
- Baeck M, Marot L, Nicolas JF, Pilette C, Tennstedt D, Goossens A.
Allergic hypersensitivity to topical and systemic corticosteroids: a
review. Allergy 2009;64(7):978-994.
- Baker A, Empson M, The R, Fitzharris P. Skin testing for immediate
hypersensitivity to corticosteroids: a case series and literature
review. Clin Exp Allergy 2015;45(3):669-676.
- Patel A, Bahna SL. Immediate hypersensitivity reactions to
corticosteroids. Ann Allergy Asthma Immunol 2015;115(3):178-182
e173.
- Aranda A, Mayorga C, Ariza A, Dona I, Blanca-Lopez N, Canto G, et al.
IgE-mediated hypersensitivity reactions to methylprednisolone.Allergy 2010;65(11):1376-1380.
- Venturini M, Lobera T, del Pozo MD, Gonzalez I, Blasco A. Immediate
hypersensitivity to corticosteroids. J Investig Allergol Clin
Immunol 2006;16(1):51-56.
- Rachid R, Leslie D, Schneider L, Twarog F. Hypersensitivity to
systemic corticosteroids: an infrequent but potentially
life-threatening condition. J Allergy Clin Immunol2011;127(2):524-528.
- Li PH, Wagner A, Thomas I, Watts TJ, Rutkowski R, Rutkowski K. Steroid
Allergy: Clinical Features and the Importance of Excipient Testing in
a Diagnostic Algorithm. J Allergy Clin Immunol Pract2018;6(5):1655-1661.
- Angel-Pereira D, Berges-Gimeno MP,
Madrigal-Burgaleta R, Urena-Tavera MA, Zamora-Verduga M,
Alvarez-Cuesta E. Successful rapid desensitization to
methylprednisolone sodium hemisuccinate: a case report. J
Allergy Clin Immunol Pract 2014;2(3):346-348.
- Guvenir H, Misirlioglu ED, Aydin
F, Ece D, Cakar N, Kocabas CN. Successful methylprednisolone
desensitization in a pediatric patient. Pediatr Allergy Immunol2017;28(3):305-306.
- Barbaud A, Waton J. Systemic
Allergy to Corticosteroids: Clinical Features and Cross Reactivity.
Curr Pharm Des. 2016;22(45):6825-6831.
- Padial A, Posadas S, Alvarez J,
Torres MJ, Alvarez JA, Mayorga C, et al. Nonimmediate reactions to
systemic corticosteroids suggest an immunological mechanism.Allergy 2005;60(5):665-670.
- Zhai Z, Li C, Chen Y, Gerotziafas G, Zhang Z, Wan J, et al. Prevention
and Treatment of Venous Thromboembolism Associated with Coronavirus
Disease 2019 Infection: A Consensus Statement before Guidelines.Thromb Haemost 2020.
- Bircher AJ, Harr T, Hohenstein L,
Tsakiris DA. Hypersensitivity reactions to anticoagulant drugs:
diagnosis and management options. Allergy2006;61(12):1432-1440.
- Trautmann A, Seitz CS. Heparin
allergy: delayed-type non-IgE-mediated allergic hypersensitivity to
subcutaneous heparin injection. Immunol Allergy Clin North Am2009;29(3):469-480.
- Bank I, Libourel EJ, Middeldorp S,
Van Der Meer J, Buller HR. High rate of skin complications due to
low-molecular-weight heparins in pregnant women. J Thromb
Haemost 2003;1(4):859-861.
- Tan E, Thompson G, Ekstrom C,
Lucas M. Non-immediate heparin and heparinoid cutaneous allergic
reactions: a role for fondaparinux. Intern Med J2018;48(1):73-77.
- Kim KH, Lynfield Y.
Enoxaparin-induced generalized exanthem. Cutis2003;72(1):57-60.
- Seitz CS, Brocker EB, Trautmann A.
Management of allergy to heparins in postoperative care: subcutaneous
allergy and intravenous tolerance. Dermatol Online J2008;14(9):4.
- Rodriguez-Fernandez A, Sanchez-Dominguez M, Torrado-Espanol I,
Noguerado-Mellado B, Rojas-Perez-Ezquerra P. Clinical Patterns of
Heparin Allergy: Cross-reactivity Between Low-Molecular-Weight
Heparins and Unfractionated Heparins. J Investig Allergol Clin
Immunol 2019;29(2):132-134.
- Ronceray S, Dinulescu M, Le Gall
F, Polard E, Dupuy A, Adamski H. Enoxaparin-Induced DRESS Syndrome.Case Rep Dermatol 2012;4(3):233-237.
- Bidaki R, Saeidi SA, Zarch MB.
Delirious State and Agitation Following Heparin Induced
Stevens-Johnson Syndrome. J Clin Diagn Res 2017;11(5):VL01.
- Greinacher A, Potzsch B, Amiral J,
Dummel V, Eichner A, Mueller-Eckhardt C. Heparin-associated
thrombocytopenia: isolation of the antibody and characterization of a
multimolecular PF4-heparin complex as the major antigen. Thromb
Haemost 1994;71(2):247-251.
- Greinacher A. Heparin-Induced
Thrombocytopenia. N Engl J Med 2015;373(19):1883-1884.
- Martel N, Lee J, Wells PS. Risk
for heparin-induced thrombocytopenia with unfractionated and
low-molecular-weight heparin thromboprophylaxis: a meta-analysis.Blood 2005;106(8):2710-2715.
- Berkun Y, Haviv YS, Schwartz LB,
Shalit M. Heparin-induced recurrent anaphylaxis. Clin Exp
Allergy 2004;34(12):1916-1918.
- Anders D, Trautmann A. Allergic
anaphylaxis due to subcutaneously injected heparin. Allergy
Asthma Clin Immunol 2013;9(1):1.
- Cesana P, Scherer K, Bircher AJ.
Immediate Type Hypersensitivity to Heparins: Two Case Reports and a
Review of the Literature. Int Arch Allergy Immunol2016;171(3-4):285-289.
- Leguisamo S, Prados Castano M,
Pinero Saavedra M, Cimbollek S. Recurrent Anaphylaxis Due to
Enoxaparin. J Investig Allergol Clin Immunol2015;25(4):297-299.
- Caballero MR, Fernandez-Benitez M. Allergy to heparin: a new in vitro
diagnostic technique. Allergol Immunopathol (Madr)2003;31(6):324-328.
- Kishimoto TK, Viswanathan K, Ganguly T, Elankumaran S, Smith S, Pelzer
K, et al. Contaminated heparin associated with adverse clinical events
and activation of the contact system. N Engl J Med2008;358(23):2457-2467.
- Schindewolf M, Lindhoff-Last E, Ludwig RJ, Boehncke WH.
Heparin-induced skin lesions. Lancet2012;380(9856):1867-1879.
- Parekh K, Burkhart HM, Hatab A, Ross A, Muller BA. Heparin allergy:
successful desensitization for cardiopulmonary bypass. J Thorac
Cardiovasc Surg2005;130(5):1455-1456.
- Patriarca G, Rossi M, Schiavino D,
Schinco G, Fais G, Varano C, et al. Rush desensitization in heparin
hypersensitivity: a case report. Allergy 1994;49(4):292-294.
- Gresele P, Momi S, Falcinelli E. Anti-platelet therapy:
phosphodiesterase inhibitors. Br J Clin Pharmacol2011;72(4):634-646.
- Tonew E, Indulen MK, Dzeguze DR.
Antiviral action of dipyridamole and its derivatives against influenza
virus A. Acta Virol 1982;26(3):125-129.
- Fata-Hartley CL, Palmenberg AC.
Dipyridamole reversibly inhibits mengovirus RNA replication. J
Virol 2005;79(17):11062-11070.
- Liu X, Li Z, Liu S, Sun J, Chen Z,
Jiang M, et al. Potential therapeutic effects of dipyridamole in the
severely ill patients with COVID-19. Acta Pharm Sin B 2020.
- Salava A, Alanko K, Hyry H.
Dipyridamole-induced eczematous drug eruption with positive patch test
reaction. Contact Dermatitis 2012;67(2):103-104.
- Angelides S, Van der Wall H,
Freedman SB. Acute reaction to dipyridamole during myocardial
scintigraphy. N Engl J Med 1999;340(5):394.
- Weinmann P, Moretti JL, Leynadier
F. Anaphylaxis-like reaction induced by dipyridamole during myocardial
scintigraphy. Am J Med 1994;97(5):488.
- Pichler WJ. Immune pathomechanism and classification of drug
hypersensitivity. Allergy 2019;74(8):1457-1471.
- Trautmann A, Benoit S, Goebeler M, Stoevesandt J. !Treating through!
Decision and follow-up in antibiotic therapy-associated exanthemas. J
Allergy Clin Immunol Pract 2017: 5(6):1650-1656.